RYAH Group (CSE: RYAH), a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry, will be collaborating with the University of Milan, Italy, on a new wellness line of topical patches. The partnership will be testing the permeation and effectiveness of the patches, which RYAH developed for its Smart Patch system. University scientists are focused on determining the permeation effectiveness of vitamin and nutraceutical patches as an alternative slow-release, nondigested solution to consumer intake; they will also use the RYAH Smart Patch “boost capability” to monitor and calculate the impact that precise, intermittent heat has on the delivery of the patch loadings. According to the announcement, RYAH’s Smart Patch is an IoT-powered device that enables users to monitor and track their patch formulation usage, body location of patch, length of use and personal effectiveness. The Smart Patch also features a prescheduled “boost” capability for specific formulations that may experience increased permeability with a precise, controlled, and gentle heating capability. “We are pleased to be engaging in another meaningful research project with our partners at the University of Milan,” said RYAH Group CEO Gregory Wagner in the press release. “This new project follows an ongoing, ambitious collaboration with the Department of Chemical Analysis led by Professor Gabriella Roda, with the objective to publish a scientific study on the performance of the RYAH Smart Medical inhaler. RYAH remains committed to providing effective delivery solutions combined with powerful data insights across a wide range of medicines, vitamins and nutraceuticals. The development of our wellness line combined with the RYAH Smart Patch system, is a perfect example of our commitment to keep current with important consumer trends in this expanding industry.”
To view the full press release, visit https://ibn.fm/CFo54
About RYAH Group Inc.
RYAH is a connected device, and big data and technology company focused on valuable, captive, anonymized data analysis in the global medical plant and nutraceutical intake industry. Its robust artificial intelligence platform aggregates and correlates Health Insurance Portability and Accountability Act (“HIPAA”)-compliant patient data, which is intended to help doctors personalize plant-based treatments to better predict treatment outcomes. The data collection is relevant for clinics, doctors, dispensaries and pharmaceutical companies, as well as licensed processors (“LPs”) to monitor and manage formulation effects on patients and demographics. RYAH gathers deep and insightful data on the complete patient session and formulation life cycle. For more information about the company, please visit www.RyahGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
